• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (CelloPub=CLPUB00738; PubMed=9802058).
  

PubMed=7634381; DOI=10.1007/BF00686188
Houghton P.J., Cheshire P.J., Hallman J.D. 2nd, Lutz L., Friedman H.S., Danks M.K., Houghton J.A.
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
Cancer Chemother. Pharmacol. 36:393-403(1995)

CLPUB00738
Nitiss K.C.
Oncogenic changes and induction of differentiation in pediatric astrocytic cell lines.
Thesis PhD (1997); University of Southern California Los Angeles; Los Angeles; USA

PubMed=9220028; DOI=10.1016/S0303-7207(97)00080-4
Sharif T.R., Luo W., Sharif M.
Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway.
Mol. Cell. Endocrinol. 130:119-130(1997)

PubMed=9802058
McPake C.R., Tillman D.M., Poquette C.A., George E.O., Houghton J.A., Harris L.C.
Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status.
Oncol. Res. 10:235-244(1998)

PubMed=10402232; DOI=10.3892/ijo.15.2.237
Sharif T.R., Sharif M.
Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples.
Int. J. Oncol. 15:237-243(1999)

PubMed=10933967; DOI=10.1006/mthe.2000.0064
Pawlik C.A., Iyengar R.V., Krull E.J., Mason S.E., Khanna R., Harris L.C., Potter P.M., Danks M.K., Guichard S.M.
Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
Mol. Ther. 1:457-463(2000)

PubMed=11306486
Iyengar R.V., Pawlik C.A., Krull E.J., Phelps D.A., Burger R.A., Harris L.C., Potter P.M., Danks M.K.
Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
Cancer Res. 61:3045-3052(2001)

PubMed=20922763; DOI=10.1002/pbc.22801; PMCID=PMC3005554
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)